Cannara Biotech announces DTC eligibility to facilitate U.S. investor access

Cannara Biotech (LOVFF) announced that the common shares of the Company are now eligible for electronic clearing and settlement in the United States through The Depository Trust Company. DTC eligibility will expand access and reduce costs for U.S. investors purchasing Cannara shares enhancing Cannara’s trading liquidity. As a subsidiary of the Depository Trust & Clearing Corporation, DTC facilitates the electronic clearing and settlement of publicly traded securities in the United States. With this eligibility, the Company’s shares can now be traded through a wider network of U.S. brokerage firms, enabling faster transactions and broader market access. Further to its news release dated October 2, 2025, the Company is also pleased to announce the completion of the issuance of 3,462,763 Common Shares to Olymbec Investments, at an issue price of $1.80 per share, in full payment of approximately $6.2 million of indebtedness, consisting of $4.7 million in principal and approximately $1.5 million in accrued interest, under its convertible debenture issued to Olymbec, the proceeds of which were used to purchase Cannara’s mega production facility in Valleyfield, Quebec.